TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02404584

Intervention type: GENETIC
Intervention: Blood drawn for genotyping
Description: Blood will be drawn for genotyping (predefined list of genes) just before the start of sunitinib (baseline).

Intervention type: BIOLOGICAL
Intervention: Blood drawn for pharmacokinetic measures
Description: Blood will be drawn for pharmacokinetic measures between CmD15 and CmD28 of each sunitinib cycle.\*~\*Each patient will undergo several cycles of treatment with sunitinib during the monitoring period as part of routine care (= 18 months; the number of cycles per patient can vary, which is normal). Each cycle and each day of the cycle will be annotated with the letters C and D, respectively, followed by a number in chronological order. Thus C1D1 refers to to the first day of the first cycle; CmDn will be the nth day of the mth cycle.
Study: NCT03200795

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rebound exercise
Description: Each participant will undergo 3 sessions a week for 8 weeks with each session lasting 20 minutes. Bouncing frequency will be determined by signals from an metronom and will be set at between 90 and 120 bounces per minute. Heart rate training zone will be maintained, during the exercise, at moderate intensity of 40-60% and will be calculated using the Karvonen formula (\[Heart rate reserve x training percentage\] + resting heart rate)(Nuhu \& Maharaj, 2017).~The exercise will involve bouncing on the center portion of the mini trampoline (Portable 2013 Model Half-Fold Cellerciser with feet slightly apart and knees in full extension. Each foot strike equaled one step or bounce with step height, this will be defined as the distance between the foot at maximum height of jump and the bed of the center of the trampoline ranging between 10 and 15 cm (Nuhu \& Maharaj, 2017).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circuit training exercise
Description: Participants will be instructed to exhale while lifting a weight and inhale while lowering it, to minimize blood pressure excursions, and to rest for 2 to 3 minutes between sets. Participants will perform 1 set per resistance exercise three time weekly for the first 2 weeks and 4 sets of each resistance exercise three time weekly during weeks 3 and 4. Resistance will be increase by 5 to 10 kg when the participant could perform more than 15 repetitions while maintaining proper form.~All aerobic activities of the circuit training will be performed on a cycle ergometer or treadmill. Participants are free to vary the machine used from one visit to the next. Exercise intensity will be standardized by using heart rate monitors (Polar Electro Oy) that will display the participant's heart rate and emitted a warning signal when the heart rate was outside the prescribed training zone, thus guiding the participant in adjusting the workload up or down to achieve the desired intensity.
Study: NCT03457636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline Anhydrous 40 MG
Description: One Oracea Capsule (40 mg) should be taken once daily in the morning on an empty stomach, preferably at least one hour prior to or two hours after meals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene/Benzoyl Peroxide Gel 0.3-2.5%
Description: Epiduo Forte should be applied in a thin layer to affected areas of the face and/or trunk once daily after washing, with care taken to avoid the eyes, lips, and mucous membranes
Study: NCT00572728

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT
Description: Undergo 18F-FLT PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FLT
Description: Undergo 18F-FLT PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET
Description: Undergo 18F-FLT PET/CT
Study: NCT02143141

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: duramorph
Description: duramorph 150 mcg given with spinal anesthetic, then receipt of placebo capsules postoperatively. evaluation postoperative day 1 for measurement of itching, nausea, vomiting, pain and itching.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo in an equal volume to that of duramorph 150 mcg given with spinal anesthetic, then receipt of oral acetaminophen 1000mg during first 24 hours postoperatively. evaluation postoperative day 1 for measurement of itching, nausea, vomiting, pain and itching.
Study: NCT02732184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-ArgI-PEG modified human arginase I
Study: NCT01963936

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supreme LMA

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Facial mask
Study: NCT01553721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: udenafil
Description: Phase IIa - Udenafil Dose 1, Dose 2(Single dose)~Phase IIb - Udenafil(BID)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Phase IIa - placebo Phase IIb - placebo
Study: NCT01877031

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: A magnetically tracked needle with an associated virtual image will be superimposed on the ultrasound image to give the user a better idea of the position of the needle.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Standard of Care - Ultrasound guided intervention
Study: NCT01000519

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Training
Description: 18 sessions over 2 months period. Each session consist of 50 minutes of aerobic training at 65-70 % of maximum predicted heart rate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive resistance training
Description: 18 sessions completed in 2 months. each session consists of 50 minutes of resistance training which is made up of 3 sets of 10 repetitions of nine resistive exercises using machines and free weights at 65-70% of 1-repetitive maximum.
Study: NCT03431142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Additional 9 months of clopidogrel monotherapy after 9-12 months of DAPT (aspirin+clopidogrel)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel+aspirin
Description: Additional 9 months of clopidogrel plus aspirin after 9-12 months of DAPT (aspirin+clopidogrel)
Study: NCT02778373

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitargo ®, Swecarb AB, Karlskrona, Sweden

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DE15 maltodextrin, Matrin® M160, Grain Processing Corporation, Muscatine, IA

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Water
Study: NCT02996500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06650833
Description: Investigational

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06650833
Description: Investigational

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06650833
Description: Investigational

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06650833
Description: Investigational

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tofacitinib
Description: Investigational
Study: NCT04459104

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low glycemic load
Description: Participants will be given test beverages containing 50gr of isomaltulose (low glycemic index = 32). Isomaltulose powder will be dissolved in 250mL water, and participants will be instructed to consume this beverage within 5 minutes. Blood glucose levels will be collected at 15, 30, 45, 60, 90, and 120 minutes after consumption of the beverages. The first two drops of blood will be discarded, the third drop will be used for testing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low glycemic load
Description: Participants will be given test beverages containing 50gr of isomaltulose (low glycemic index = 32). Isomaltulose powder will be dissolved in 250mL water, and participants will be instructed to consume this beverage within 5 minutes. Blood glucose levels will be collected at 15, 30, 45, 60, 90, and 120 minutes after consumption of the beverages. The first two drops of blood will be discarded, the third drop will be used for testing.
Study: NCT04694846

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco Cessation Counseling
Description: Receive counseling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04459104

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low glycemic load
Description: Participants will be given test beverages containing 50gr of isomaltulose (low glycemic index = 32). Isomaltulose powder will be dissolved in 250mL water, and participants will be instructed to consume this beverage within 5 minutes. Blood glucose levels will be collected at 15, 30, 45, 60, 90, and 120 minutes after consumption of the beverages. The first two drops of blood will be discarded, the third drop will be used for testing.
Study: NCT05417035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebido
Description: To evaluate if traditional treatment induces puberty similary to newer treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebido
Description: To evaluate if traditional treatment induces puberty similary to newer treatment
Study: NCT02654860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol 3%
Description: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol 3%
Description: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol 3%
Description: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection containing Saline solution 0.9%
Description: Injection containing sterile solution of Saline Solution 0.9 %. Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric Bupivacaine HCl 0.5%
Description: NIMP, spinal anaesthetic before the surgical procedure
Study: NCT04459104

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High glycemic load
Description: Participants will be given test beverages containing 50gr sucrose (high glycemic index = 65). Sucrose powder will be dissolved in 250mL water, and participants will be instructed to consume this beverage within 5 minutes. Blood glucose levels will be collected at 15, 30, 45, 60, 90, and 120 minutes after consumption of the beverages. The first two drops of blood will be discarded, the third drop will be used for testing.
Study: NCT02654860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric Bupivacaine HCl 0.5%
Description: NIMP, spinal anaesthetic before the surgical procedure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric Bupivacaine HCl 0.5%
Description: NIMP, spinal anaesthetic before the surgical procedure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hyperbaric Bupivacaine HCl 0.5%
Description: NIMP, spinal anaesthetic before the surgical procedure
Study: NCT01235832

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Avocado Diet
Description: The avocado diet will be designed to ensure that all subjects incorporate 1 avocado (\~136g) per day into a moderate fat diet. Both the Lower-Fat diet and avocado diet will be matched for SFA and dietary cholesterol, but will differ in total fat, primarily MUFA as provided by the avocado. The moderate fat plus avocado diet will provide 34% of calories from total fat, 18% calories from MUFA, and 9% calories from PUFA.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lower-Fat Diet
Description: The Lower-Fat diet will provide \~24% of calories from fat and meet the SFA and cholesterol recommendations of a Step-II diet recommended by the National Heart, Lung, and Blood Association's National Cholesterol Education Program. SFA will provide 7% of calories, and cholesterol will be less than 200mg/day. Vegetables and fruits in the Lower-Fat diet will be selected from foods that are low in antioxidants.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Fat Diet
Description: This diet is designed to be the control diet for the avocado diet and will have an identical fatty acid profile. MUFA-enriched food (fats) will be substituted for avocado. The substitution foods will not contain antioxidant or cholesterol-lowering components similar to those in avocado.
Study: NCT02767882

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Bolus injection of different dose of dexamethasone will be given intravenously prior to incision.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Bolus injection of different dose of dexamethasone will be given intravenously prior to incision.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Bolus injection of 4ml 0.9% saline will be given intravenously prior to incision.
Study: NCT02013479

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SelenoPRECISE
Description: Produced by Pharma Nord ApS, Vejle, Denmark

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Produced by Pharma Nord ApS, Vejle, Denmark
Study: NCT04694846

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life Assessment
Description: Ancillary studies
Study: NCT02356003

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low frequency repetitive transcranial magnetic stimulation
Description: Baseline high-resolution anatomical magnetic resonance images will allow individualized neuronavigation (Brainsight 2, Rogue Research, Montreal QC) to co-register the transcranial magnetic stimulation Airfilm coil (Magistim, UK) precisely to the supplementary motor area as defined by functional magnetic resonance imaging. Interventional low frequency repetitive transcranial magnetic stimulation parameters will be: intensity 100% resting motor threshold, frequency 1 Hz, duration = 20 minutes (1200 stimulations). Treatments will occur on each weekday at the same time of day for three weeks (15 total). These are standard parameters for low frequency repetitive transcranial magnetic stimulation and are well tolerated in children.
Study: NCT04459104

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High glycemic load
Description: Participants will be given test beverages containing 50gr sucrose (high glycemic index = 65). Sucrose powder will be dissolved in 250mL water, and participants will be instructed to consume this beverage within 5 minutes. Blood glucose levels will be collected at 15, 30, 45, 60, 90, and 120 minutes after consumption of the beverages. The first two drops of blood will be discarded, the third drop will be used for testing.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High glycemic load
Description: Participants will be given test beverages containing 50gr sucrose (high glycemic index = 65). Sucrose powder will be dissolved in 250mL water, and participants will be instructed to consume this beverage within 5 minutes. Blood glucose levels will be collected at 15, 30, 45, 60, 90, and 120 minutes after consumption of the beverages. The first two drops of blood will be discarded, the third drop will be used for testing.
Study: NCT00423475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin acetate

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT03595085

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: catheter directed fragmentation and thrombolysis
Description: A(6)F multipurpose catheter will be advanced over a guide wire under fluoroscopic guidance and used to measure right heart and pulmonary artery pressures, then mechanical catheter fragmentation will be done using a pigtail catheter. The catheter will be quickly spun manually so as to fragment the central thrombus and establish initial flow into pulmonary artery. After ensuring initial flow, Initial bolus dose of streptokinase (250.000 international unit) will be given over 10 min followed by continuous infusion of (100.000 international unit per hour)for 24 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Streptokinase
Description: intravenous streptokinase at a dose of 250 000 international unit as a loading dose over 30 minutes, followed by 100 000 international unit per hour over 12-24 hours
Study: NCT05278728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: 200,400,600 or 800mg weekly until progression or AEs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180mg/m2 d1, Q2w until progression or AEs or maximum 6 cycles
Study: NCT03599492

Intervention type: DIAGNOSTIC_TEST
Intervention: SMART Pill Pre-TIPS
Description: Assessment of motility with Smart Pill, which will be read and confirmed by gastroenterologist trained to interpret motility studies

Intervention type: DIAGNOSTIC_TEST
Intervention: SMART Pill Post TIPS
Description: Assessment of motility with Smart Pill, which will be read and confirmed by gastroenterologist trained to interpret motility studies
Study: NCT02485171

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAFEWALKER
Description: Medical device walking aids.
Study: NCT01205386

Intervention type: DEVICE
Intervention: 1. CROSSER System
Description: The Crosser system will be used to recanalize the chronic total occlusion in the SFA (superficial femoral artery). The IVUS (Intravascular Ultrasound Imaging) System will be used in the treated occlusion after the Crosser to generate real-time images of the artery.
Study: NCT01209130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCDT2980S
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCDT2980S
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Intravenous repeating dose
Study: NCT02592083

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen or Aromatase Inhibitor or Aromatase Inhibitor + goserelin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen or Aromatase Inhibitor or Aromatase Inhibitor + goserelin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen or Aromatase Inhibitor or Aromatase Inhibitor + goserelin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Study: NCT04097236

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Qualitative and quantitative assessment of gastric content volume with bed elevation
Description: Ultrasound examination of the gastric antrum are performed 3 minutes after the ingestion of a volume of water (either 0, 50, 100, 150, or 200 milliliters (ml), determined by randomization). The procedure is repeated three times (three different volumes, the same volumes for each session with randomized order for each session).
Study: NCT04694846

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality of Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard treatment
Study: NCT04097236

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Qualitative and quantitative assessment of gastric content volume without bed elevation
Description: Ultrasound examination of the gastric antrum are performed 3 minutes after the ingestion of a volume of water (either 0, 50, 100, 150, or 200 milliliters (ml), determined by randomization). The procedure is repeated three times (three different volumes, the same volumes for each session with randomized order for each session).
Study: NCT00049582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT04728503

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5-Minute Mindful Movement Video
Description: 5 minute video includes a brief verbal introduction to mindfulness and then guides participants through a mindful movement exercise to facilitate grounding in the present moment and activation of the parasympathetic nervous system.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Written Educative Materials
Description: 1 page written educative material about the benefits of mindfulness to serve as a control.
Study: NCT03050710

Intervention type: DEVICE
Group type: OTHER
Intervention: Princess® VOLUME Lidocaine
Description: Princess® VOLUME Lidocaine injections up to 10 ml given to the patients at baseline, and touch-up at week 2, if applicable
Study: NCT03252912

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood samples
Description: Two EDTA tubes (5 mL) and two dried tubes (5mL) will be will be taken the same day as the first lumbar .
Study: NCT00963781

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Endeavor Stent
Description: The study population was to consist of 900 consecutive, eligible patients with ischemic heart disease scheduled to undergo elective percutaneous coronary revascularization and amenable to treatment with an Endeavor drug-eluting stent with reference vessel diameter between 2.5 and 4.0 mm. Patients will be assigned to 6 month duration of post-procedure thienopyridine treatment with indefinite aspirin (minimum 81 mg daily) according to protocol. Recruitment was terminated early due to difficulty recruiting patients and difficulty achieving patient compliance with the six month anti-platelet protocol.
Study: NCT02341404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2-hydroxyflutamide (2-HOF)
Description: Two components are mixed, transferred to a syringe and administered with injection into the prostate